Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of AZD4785 in Advanced Solid Tumours
NCT03101839Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- May 2017
- Primary completion
- Jan 2019
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of azd4785 in solid tumor (advanced stage) and non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Primary endpoint: Maximum Tolerated Dose at 28 days. Started May 2017; status: completed.
02
Drugs
azd4785
03
Conditions
solid tumor (advanced stage)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03101839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03101839.